ClinicalTrials.gg
CompletedNCT01630135Updated Jan 11, 2017Results posted

Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

A Phase 3 interventional study of Fluticasone furoate and Placebo in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 22 sites in Japan. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial — none open to participants now, none under way, none of them phase 3. fluticasone furoate · Rhinitis, Allergic, Perennial.

Enrollment
9th of 15
261 · median 288
Started
2012
the only one that year
Phase 3
11 of 15
none open now
Registered
15th of 15
by date
Lead sponsor
15 of 15
GlaxoSmithKline

Among the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial, this one is the 9th largest by enrollment, is the only one that started in 2012, is one of 11 in phase 3, and was the 15th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

None of the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing fluticasone furoate in Rhinitis, Allergic, Perennial as a file.
02

Study summary

Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to \< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.

03

Conditions studied

  • Rhinitis, Allergic, Perennial
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6 to \<15 years of age, male or eligible female (females of must commit to consistent and correct use of an acceptable method of ), outpatient
  • Diagnosis of perennial allergic rhinitis: A positive test response to house dust and/or dust mites on serum antigen-specific IgE antibody test at Visit 1. One year or more clinical history of perennial allergic rhinitis. A positive test result on nasal eosinophil count at Visit 1/1A.
  • Either subject's parent/guardian who signed ICF or subject is able to complete assessments on the patient diary through the study.
  • \< 2xULN; alkaline phosphatase and \<= 1.5xULN
  • Average of 3TNSS is >= 4.0 in the last consecutive 4 days prior to Visit 2.
  • Completion of the patient diary on >= 3 days of the last consecutive 4 days prior to Visit 2

Exclusion criteria

Exclusion Criteria:

  • Has a seasonal pollen as an allergen
  • A nose disorder that could affect the assessment of the study medication or eye or nose surgery (within 3 months prior to Visit 1)
  • Bacterial or viral infection of upper respiratory tract or eye
  • Concurrent disease/abnormalities: uncontrolled disease
  • Known to or any in the product
  • Has recent participation in a study and/or exposure to an investigational study drug within 3 months prior to Visit 1
  • Use of the following medication and/or its combination drug within the specified time:

Anti-IgE (Within 6 months prior to Visit 1), medications or Systemic corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to Visit 1

  • Affiliation with Investigator's Site: Relative or employee
  • History of alcohol or drug abuse, children in care or in the opinion of the investigator (sub-investigator), inappropriate to be enrolled in the study.
  • Average of 3TNSS is >= 8.0 in the last consecutive 4 days prior to Visit 2.
  • Bacterial or viral infection of upper respiratory tract or eye during the screening period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    GW685698X

    GW685698X 55mcg/day

    Drug: Fluticasone furoate

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.

    Time frame: Baseline through the entire treatment period (2 weeks)

Secondary outcomes

  1. Mean Change From Baseline in 3TNSS at Week 1 and Week 2

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For Week 1 and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score at Week 1 and Week 2 minus the score at Baseline.

    Time frame: Baseline; Week 1 and Week 2

  2. Mean Percent Change From Baseline in 3TNSS Over the Entire Treatment Period, at Week 1, and at Week 2

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  3. Mean Change From Baseline in 3TNSS at the Indicated Days

    The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). Change from Baseline was calculated as the mean score at the indicated day minus the score at Baseline.

    Time frame: Baseline; Days 1 through 14

  4. Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, at Week 1, and at Week 2

    The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  5. Mean Percent Change From Baseline in the 4TNSS Over the Entire Treatment Period, at Week 1, and at Week 2

    The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 4TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  6. Mean Change From Baseline in Rhinorrhea, Nasal Congestion, Sneezing, and Nasal Itching Over the Entire Treatment Period (ETP), at Week 1, and at Week 2

    Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  7. Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, at Week 1, and at Week 2

    Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  8. Mean Change From Baseline (BL) in the Total Ocular Symptom Score (TOSS) for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2

    Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  9. Mean Percent Change From Baseline (BL) in the TOSS Over the Entire Treatment Period, at Week 1, and at Week 2

    Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100. Par. with a BL TOSS of 0 were not analyzed because percent change from BL could not be calculated.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  10. Mean Percent Change From Baseline (BL) in the TOSS for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2

    Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  11. Mean Change From Baseline in the Individual Ocular Symptom Scores (Eye Itching, Tearing, and Redness) Over the Entire Treatment Period, at Week 1, and at Week 2

    Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  12. Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, at Week 1, and at Week 2

    The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline through the entire treatment period (2 weeks), Week 1, and Week 2

  13. Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge) at Baseline, Week 1, and Week 2/EW

    Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).

    Time frame: Baseline, Week 1, and Week 2/Early Withdrawal (EW)

  14. Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator

    The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

    Time frame: Week 2/EW

  15. Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant

    The participant's parent/guardian who signed the ICF or the participant themself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

    Time frame: Week 2/EW

07

Results

Posted May 1, 2013

Participant flow

Participant flow — Overall Study
MilestoneFluticasone Furoate 55 µg Per DayPlacebo
Started131130
Completed131128
Not completed02
Withdrew: Protocol-defined stopping criteria met02

Outcome measures

PrimaryMean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.

Time frame:
Baseline through the entire treatment period (2 weeks)
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period-1.98 ± 0.12-0.89 ± 0.12
Statistical analysis
  • Fluticasone Furoate 55 µg Per Day vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -1.089 · 95% CI -1.41 to -0.76The analysis was based on an analysis of covariance (ANCOVA) with a model adjusting for Treatment, Baseline, Age, and Sex.
SecondaryMean Change From Baseline in 3TNSS at Week 1 and Week 2

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For Week 1 and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score at Week 1 and Week 2 minus the score at Baseline.

Time frame:
Baseline; Week 1 and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in 3TNSS at Week 1 and Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Week 1, n=131, 130-1.60 ± 0.12-0.70 ± 0.12
Week 2, n=131, 128-2.38 ± 0.13-1.10 ± 0.13
SecondaryMean Percent Change From Baseline in 3TNSS Over the Entire Treatment Period, at Week 1, and at Week 2

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline in 3TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
Percent changeFluticasone Furoate 55 µg Per DayPlacebo
Entire treatment period, n=131, 130-39.76 ± 2.38-17.74 ± 2.36
Week 1, n=131, 130-31.96 ± 2.46-13.89 ± 2.44
Week 2, n=131, 128-47.89 ± 2.70-21.95 ± 2.70
SecondaryMean Change From Baseline in 3TNSS at the Indicated Days

The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). Change from Baseline was calculated as the mean score at the indicated day minus the score at Baseline.

Time frame:
Baseline; Days 1 through 14
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in 3TNSS at the Indicated Days
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Day 1, n=130, 130-0.71 ± 0.13-0.52 ± 0.12
Day 2, n=131, 130-1.33 ± 0.14-0.41 ± 0.14
Day 3, n=131, 130-1.53 ± 0.15-0.61 ± 0.15
Day 4, n=131, 130-1.69 ± 0.15-0.77 ± 0.15
Day 5, n=131, 130-1.89 ± 0.16-0.77 ± 0.16
Day 6, n=131, 130-1.95 ± 0.16-0.97 ± 0.16
Day 7, n=131, 130-2.05 ± 0.16-0.87 ± 0.16
Day 8, n=131, 128-2.14 ± 0.16-1.05 ± 0.16
Day 9, n=131, 128-2.29 ± 0.16-1.07 ± 0.16
Day 10, n=131, 128-2.32 ± 0.16-1.01 ± 0.16
Day 11, n=131, 128-2.36 ± 0.16-1.19 ± 0.16
Day 12, n=131, 128-2.54 ± 0.15-1.21 ± 0.15
Day 13, n=122, 123-2.47 ± 0.16-1.20 ± 0.16
Day 14, n=105, 115-2.65 ± 0.17-0.93 ± 0.16
SecondaryMean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, at Week 1, and at Week 2

The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=131, 130-2.40 ± 0.15-1.01 ± 0.15
Week 1, n=131, 130-1.94 ± 0.15-0.74 ± 0.15
Week 2, n= 131, 128-2.89 ± 0.16-1.29 ± 0.16
SecondaryMean Percent Change From Baseline in the 4TNSS Over the Entire Treatment Period, at Week 1, and at Week 2

The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 4TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire treatment period (Weeks 1 and 2), Week 1, and Week 2, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline in the 4TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
Percent changeFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=131, 130-40.42 ± 2.46-16.09 ± 2.44
Week 1, n=131, 130-32.55 ± 2.54-11.54 ± 2.52
Week 2, n= 131, 128-48.58 ± 2.78-20.92 ± 2.78
SecondaryMean Change From Baseline in Rhinorrhea, Nasal Congestion, Sneezing, and Nasal Itching Over the Entire Treatment Period (ETP), at Week 1, and at Week 2

Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Rhinorrhea, Nasal Congestion, Sneezing, and Nasal Itching Over the Entire Treatment Period (ETP), at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Rhinorrhea, ETP, n=131, 130-0.69 ± 0.05-0.31 ± 0.05
Rhinorrhea, Week 1, n=131, 130-0.55 ± 0.05-0.23 ± 0.05
Rhinorrhea, Week 2, n=131, 128-0.85 ± 0.06-0.40 ± 0.06
Nasal congestion, ETP, n=131, 130-0.70 ± 0.05-0.36 ± 0.05
Nasal congestion, Week 1, n=131, 130-0.56 ± 0.05-0.29 ± 0.05
Nasal congestion, Week 2, n=131, 128-0.84 ± 0.05-0.43 ± 0.05
Sneezing, ETP, n=131, 130-0.60 ± 0.04-0.21 ± 0.04
Sneezing, Week 1, n=131, 130-0.50 ± 0.04-0.16 ± 0.04
Sneezing, Week 2, n= 131, 128-0.71 ± 0.05-0.27 ± 0.05
Nasal itching, ETP, n=131, 130-0.41 ± 0.04-0.12 ± 0.04
Nasal itching, Week 1, n=131, 130-0.33 ± 0.05-0.04 ± 0.05
Nasal itching, Week 2, n= 131, 128-0.49 ± 0.05-0.19 ± 0.05
SecondaryMean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, at Week 1, and at Week 2

Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=131, 130-0.46 ± 0.09-0.32 ± 0.09
Week 1, n=131, 130-0.31 ± 0.09-0.22 ± 0.09
Week 2, n= 131, 128-0.61 ± 0.10-0.39 ± 0.10
SecondaryMean Change From Baseline (BL) in the Total Ocular Symptom Score (TOSS) for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2

Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline (BL) in the Total Ocular Symptom Score (TOSS) for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=99, 92-0.77 ± 0.11-0.47 ± 0.11
Week 1, n=99, 92-0.56 ± 0.11-0.35 ± 0.11
Week 2, n= 99, 90-0.99 ± 0.13-0.56 ± 0.13
SecondaryMean Percent Change From Baseline (BL) in the TOSS Over the Entire Treatment Period, at Week 1, and at Week 2

Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100. Par. with a BL TOSS of 0 were not analyzed because percent change from BL could not be calculated.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline (BL) in the TOSS Over the Entire Treatment Period, at Week 1, and at Week 2
Percent changeFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=99, 92-20.97 ± 11.391.57 ± 11.64
Week 1, n=99, 92-9.20 ± 10.905.37 ± 11.14
Week 2, n= 99, 90-33.52 ± 13.27-1.70 ± 13.69
SecondaryMean Percent Change From Baseline (BL) in the TOSS for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2

Symptoms of eye itching, tearing, and redness were scored by the participant's (par.) parent/guardian who signed the ICF or the par. themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the par.'s diary. The TOSS is the sum of all 3 symptom scores and ranges from 0 to 9. The mean of the BL period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each par. was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from BL=(mean score at post-BL assessment minus score at BL) divided by the BL value \* 100.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline (BL) in the TOSS for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
Percent changeFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=99, 92-20.97 ± 11.391.57 ± 11.64
Week 1, n=99, 92-9.20 ± 10.905.37 ± 11.14
Week 2, n=99, 90-33.52 ± 13.27-1.70 ± 13.69
SecondaryMean Change From Baseline in the Individual Ocular Symptom Scores (Eye Itching, Tearing, and Redness) Over the Entire Treatment Period, at Week 1, and at Week 2

Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Individual Ocular Symptom Scores (Eye Itching, Tearing, and Redness) Over the Entire Treatment Period, at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Eye itching, Entire Treatment Period, n=131, 130-0.24 ± 0.04-0.18 ± 0.04
Eye itching, Week 1, n=131, 130-0.15 ± 0.04-0.13 ± 0.04
Eye itching Week 2, n=131, 128-0.34 ± 0.05-0.23 ± 0.05
Tearing, Entire Treatment Period, n=131, 130-0.10 ± 0.03-0.05 ± 0.03
Tearing, Week 1, n=131, 130-0.09 ± 0.03-0.03 ± 0.03
Tearing, Week 2, n=131, 128-0.11 ± 0.03-0.07 ± 0.03
Redness, Entire Treatment Period, n=131, 130-0.11 ± 0.03-0.09 ± 0.03
Redness, Week 1, n=131, 130-0.07 ± 0.03-0.07 ± 0.03
Redness, Week 2, n=130, 128-0.16 ± 0.04-0.10 ± 0.04
SecondaryMean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, at Week 1, and at Week 2

The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (Weeks 1 and 2), Week 1, and Week 2. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline through the entire treatment period (2 weeks), Week 1, and Week 2
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, at Week 1, and at Week 2
Scores on a scaleFluticasone Furoate 55 µg Per DayPlacebo
Entire Treatment Period, n=131, 130-0.43 ± 0.04-0.13 ± 0.04
Week 1, n=131, 130-0.33 ± 0.04-0.10 ± 0.04
Week 2, n=131, 128-0.53 ± 0.05-0.16 ± 0.05
SecondaryNumber of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge) at Baseline, Week 1, and Week 2/EW

Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).

Time frame:
Baseline, Week 1, and Week 2/Early Withdrawal (EW)
Reported as:
Number · participants
Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge) at Baseline, Week 1, and Week 2/EW
participantsFluticasone Furoate 55 µg Per DayPlacebo
SOITM, Baseline, Score 0, n=131, 13027
SOITM, Baseline, Score 1, n=131, 1302432
SOITM, Baseline, Score 2, n=131, 1305455
SOITM, Baseline, Score 3, n=131, 1305136
SOITM, Week 1, Score 0, n=131, 12895
SOITM, Week 1, Score 1, n=131, 1284555
SOITM, Week 1, Score 2, n=131, 1285344
SOITM, Week 1, Score 3, n=131, 1282424
SOITM, Week 2/EW, Score 0, n=131, 1301919
SOITM, Week 2/EW, Score 1, n=131, 1306245
SOITM, Week 2/EW, Score 2, n=131, 1303742
SOITM, Week 2/EW, Score 3, n=131, 1301324
COITM, Baseline, Score 0, n=131, 13022
COITM, Baseline, Score 1, n=131, 1301331
COITM, Baseline, Score 2, n=131, 1302829
COITM, Baseline, Score 3, n=131, 1308868
COITM, Week 1, Score 0, n= 131, 12852
COITM, Week 1, Score 1, n= 131, 1284543
COITM, Week 1, Score 2, n= 131, 1282327
COITM, Week 1, Score 3, n= 131, 1285856
COITM, Week 2/EW, Score 0, n=131, 130710
COITM, Week 2/EW, Score 1, n=131, 1306851
COITM, Week 2/EW, Score 2, n=131, 1301720
COITM, Week 2/EW, Score 3, n=131, 1303949
QTND, Baseline, Score 0, n=131, 13086
QTND, Baseline, Score 1, n=131, 1305253
QTND, Baseline, Score 2, n=131, 1306063
QTND, Baseline, Score 3, n=131, 130118
QTND, Week 1, Score 0, n= 131, 1283818
QTND, Week 1, Score 1, n= 131, 1285762
QTND, Week 1, Score 2, n= 131, 1283242
QTND, Week 1, Score 3, n= 131, 12846
QTND, Week 2/EW, Score 0, n=131, 1306337
QTND, Week 2/EW, Score 1, n=131, 1304957
QTND, Week 2/EW, Score 2, n=131, 1301831
QTND, Week 2/EW, Score 3, n=131, 13015
QLND, Baseline, Score 0, n=131, 13096
QLND, Baseline, Score 1, n=131, 13000
QLND, Baseline, Score 2, n=131, 1302927
QLND, Baseline, Score 3, n=131, 1309397
QLND, Week 1, Score 0, n= 131, 1283918
QLND, Week 1, Score 1, n= 131, 12825
QLND, Week 1, Score 2, n= 131, 1282427
QLND, Week 1, Score 3, n= 131, 1286678
QLND, Week 2/EW, Score 0, n=131, 1306233
QLND, Week 2/EW, Score 1, n=131, 13033
QLND, Week 2/EW, Score 2, n=131, 1302629
QLND, Week 2/EW, Score 3, n=131, 1304065
SecondaryNumber of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator

The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

Time frame:
Week 2/EW
Reported as:
Number · participants
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
participantsFluticasone Furoate 55 µg Per DayPlacebo
Significantly improved3212
Moderately improved3825
Mildly improved3631
No change2254
Mildly worse15
Moderately worse22
Significantly worse01
SecondaryNumber of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant

The participant's parent/guardian who signed the ICF or the participant themself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.

Time frame:
Week 2/EW
Reported as:
Number · participants
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
participantsFluticasone Furoate 55 µg Per DayPlacebo
Significantly improved282
Moderately improved5126
Mildly improved3448
No change1851
Mildly worse03
Moderately worse00
Significantly worse00

Adverse events

Collected over Participants were analyzed from the start of study treatment until the follow up contact (up to 3 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate 55 µg Per Day—0/131 (0%)23/131 (17.6%)
Placebo—0/130 (0%)25/130 (19.2%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventFluticasone Furoate 55 µg Per DayPlacebo
NasopharyngitisInfections and infestations6/1313/130
EpistaxisRespiratory, thoracic and mediastinal disorders2/1313/130
Alanine aminotransferase increasedInvestigations0/1312/130
Aspartate aminotransferase increasedInvestigations0/1312/130
HeadacheNervous system disorders0/1312/130
Conjunctivitis allergicEye disorders2/1310/130
BronchitisInfections and infestations1/1311/130
Otitis media acuteInfections and infestations0/1311/130
Pneumonia mycoplasmalInfections and infestations0/1311/130
Nasal discomfortRespiratory, thoracic and mediastinal disorders1/1311/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Furoate 55 µg Per DayPlaceboTotal
Mean10.0 ± 2.3210.1 ± 2.2210.1 ± 2.26
Gender
Gender(Participants)Fluticasone Furoate 55 µg Per DayPlaceboTotal
Female465197
Male8579164
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fluticasone Furoate 55 µg Per DayPlaceboTotal
Asian - Japanese Heritage131130261
08

Study locations

22 sites
  • GSK Investigational Site
    Chiba, 261-0004, Japan
  • GSK Investigational Site
    Chiba, 270-0034, Japan
  • GSK Investigational Site
    Chiba, 272-0143, Japan
  • GSK Investigational Site
    Chiba, 277-0882, Japan
  • GSK Investigational Site
    Chiba, 279-0012, Japan
  • GSK Investigational Site
    Gifu, 501-3247, Japan
  • GSK Investigational Site
    Hokkaido, 001-0923, Japan
  • GSK Investigational Site
    Hokkaido, 061-1133, Japan
  • GSK Investigational Site
    Hokkaido, 062-0034, Japan
  • GSK Investigational Site
    Kanagawa, 222-0011, Japan
  • GSK Investigational Site
    Kanagawa, 222-0031, Japan
  • GSK Investigational Site
    Kanagawa, 232-0056, Japan
  • GSK Investigational Site
    Saitama, 333-0861, Japan
  • GSK Investigational Site
    Saitama, 350-1205, Japan
  • GSK Investigational Site
    Saitama, 354-0018, Japan
  • GSK Investigational Site
    Saitama, 355-0062, Japan
  • GSK Investigational Site
    Tokyo, 114-0023, Japan
  • GSK Investigational Site
    Tokyo, 125-0052, Japan
  • GSK Investigational Site
    Tokyo, 151-0072, Japan
  • GSK Investigational Site
    Tokyo, 160-0017, Japan
  • GSK Investigational Site
    Tokyo, 170-0005, Japan
  • GSK Investigational Site
    Tokyo, 178-0064, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2012
First posted
Jun 28, 2012
Start
Jun 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
May 1, 2013
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01630135
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 28, 2012
Start date
Jun 2012
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
May 1, 2013
Last update
Jan 11, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion